Discontinued — last reported Q4 '23
Labcorp Holdings LabCorp Diagnostics — Payments for Restructuring remained flat by 0.0% to -$6.55M in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 4.8%, from -$6.25M to -$6.55M. Over 2 years (FY 2021 to FY 2023), LabCorp Diagnostics — Payments for Restructuring shows relatively stable performance with a -3.6% CAGR.
High cash outflows confirm that restructuring plans are being actively executed and paid for.
This represents the actual cash outflow associated with executing restructuring plans, such as paying severance or settl...
Used by analysts to reconcile the cash impact of restructuring charges against reported earnings.
lh_segment_labcorp_diagnostics_payments_for_restructuring| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | -$28.20M | -$25.00M | -$26.20M |
| YoY Change | — | +11.3% | -4.8% |